Mendus AB (publ) (IMMU) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you, everybody, for joining the 26Q1 webcast. Hello, everyone. So to start with the summary of Q1, we've had a very ambitious plan that we communicated end of last year that was based on the positive data that we have documented over time, including the long-term follow-up we presented end of last year of the ADVANCE2 trial that showed long-term survival in MRD-positive high-risk AML with now already nine patients beyond five years of survival. So that provided the basis for us to continue the development of the product. We are currently in a trial in a similar setting, but in combination with a drug called oral azacitidine. This is applied after high-intensity chemotherapy. The trial is called AML. 22 cadence trial or in short, the cadence trial for which we wish to recruit 20 patients in the first half of 2026. It's a bit of a bumpy recruitment in AML always. Also in this trial, we are now at 16 patients recruited and we're still aiming for 20 patients in the first half of this year, which will allow us to do a first readout of the trial. The preparations for the DIVA trial, which is in combination with less intensive first-line treatment of venetoclax and azacitidin, is on track. We will also explain in a bit more detail why this is relevant and how this positions us in the AML landscape. And for that trial, to support that trial, we have signed a contract with Helicia Newton-John Cancer Research Institute, which is the leading cancer research institute in Australia. As some of you may know, we are running multiple trials in Australia, and we've therefore also set up a daughter company called Mendes Australia, which is handling not only the practical parts and the trials in Australia, but also allows us to benefit from a very attractive tax incentive that th...